

**FLEURY S.A.**  
**Publicly Held Company**  
**Company Taxpayer's ID (CNPJ) 60.840.055/0001-31**  
**Company Registry (NIRE) 35.300.197.534**

**MATERIAL FACT**

Fleury S.A. ("Grupo Fleury" or "Company"), pursuant to paragraph 4 of article 157 of Law 6,404/76 and CVM Instruction 358/02, informs its shareholders and the market in general that, on this date, through its owned subsidiary, Fleury Centro de Procedimentos Médicos Avançados S.A ("Fleury CPMA"), entered into the Investment Agreement and Other Covenants for the acquisition of 66.7% of Vita Ortopedia Serviços Médicos Especializados Ltda. and Vita Clínicas Medicina Especializada Ltda ("Societies" or "Vita").

The valuation value of 100% of Vita for the purposes of the transaction is R\$ 136.8 million, with a relevant part of the resources composing a primary portion that will be used for organic and inorganic expansions of orthopedics services in Brazil.

With more than 20 years of history, Vita is a reference in consultations and orthopedic surgeries as well as rehabilitation sessions, with a clinical staff composed by more than 40 doctors and 80 highly qualified therapists, working through 9 units of orthopedics and physiotherapy services in Sao Paulo city.

Vita's net revenue, in the 12-month period ended on June 30, 2020, reached R\$ 42.3 million.

This acquisition reinforces the growth acceleration and expansion strategy of Grupo Fleury's presence in the healthcare chain, with increasingly complete and integrated solutions through its Platform, in addition to positioning itself with an even more robust offer in this specialty, which already has the Advanced Osteomuscular Imaging Center and the Day Clinic in Orthopedics, both services under the Fleury brand.

The conclusion of this transaction is subject to certain precedent conditions.

This acquisition is not subject to the Company's shareholders' decision, nor will it give rise to the right to withdraw, in view of the terms of item 7.11 of Official Letter CVM/SEP/No. 01/2021.

The Company will keep its shareholders and the market informed about the facts related to the transaction.

São Paulo, April 09<sup>th</sup>, 2021

**FERNANDO AUGUSTO RODRIGUES LEÃO FILHO**

Chief Financial and Investor Relations Officer